What Do Phase 1, 2, and 3 Mean in Stem Cell Clinical Trials?
- Updated November 14, 2026
- Stop 1 of 4 on the Trials, cost and insurance line
Phase 1 trials mainly test initial safety and dosing in a small group. Phase 2 trials look for early signs of effectiveness while continuing to track safety. Phase 3 trials test effectiveness more extensively, often against a comparison group, and monitor side effects in larger numbers of people. These phases are a typical framework rather than a fixed sequence; designs vary with the product and the disease, and some studies combine phases. A phase label tells you what question a study was designed to answer. It does not tell you the answer, and even a successful Phase 3 trial is not the same as FDA approval.
Why clinical research has phases
Testing a new treatment in people moves in steps because each step answers a question the next one depends on. Before asking whether a product works, researchers need to know whether it can be given safely and at what dose. Before committing hundreds of participants, they need a reasonable sign of benefit. Each step adds people, comparison and follow-up, and with them, confidence.
For drugs and biological products studied under an FDA Investigational New Drug application, the phases are defined in federal regulation at 21 CFR 312.21. Cell products studied under an IND are regulated as biological products, so this framework applies to them.
What Phase 1 is designed to answer
The regulation describes Phase 1 as the initial introduction of an investigational product into humans. These studies focus on safety, how the body handles the product and what dose can be tolerated. The regulation notes that Phase 1 typically involves 20 to 80 subjects.
With so few participants and, often, no control group, Phase 1 says little about effectiveness. Participants may report feeling better, but a small uncontrolled study cannot separate the product’s effect from time, expectation or other care.
What Phase 2 adds
Phase 2 studies evaluate effectiveness for a particular condition and continue to look for short-term side effects and risks. The regulation describes them as usually involving no more than several hundred subjects. Phase 2 is a stage at which researchers may first use a control group and choose which dose and outcomes to carry forward.
A positive Phase 2 result is encouraging but preliminary. A small early signal can shrink or disappear when a larger, controlled trial tests it, which is why Phase 3 exists.
What Phase 3 tests
Phase 3 studies are expanded trials conducted after preliminary evidence suggests effectiveness. The regulation describes them as typically involving several hundred to several thousand subjects. They are designed to gather the additional information about effectiveness and safety needed to judge the overall benefit-risk balance, often across multiple sites and with a comparison group, using outcomes that matter to patients, such as pain, function or survival.
Even then, a Phase 3 result is evidence submitted for review, not an approval. FDA approval is a separate regulatory decision about a specific product for a specific use.
The participant numbers in the regulation describe typical ranges. They are not thresholds that make a study valid or a product approvable.
How do phase labels apply specifically to investigational cell therapies?
Cell therapies fit the phase framework, but with some features that matter when you read a headline:
- Combined phases. Some cell therapy studies are registered as Phase 1/2, testing safety and early signs of effect in one study.
- Small and varied groups. Early cell therapy trials often enroll few participants, sometimes with different doses or different product batches in the same study.
- The product itself is still being defined. Unlike a chemical drug, a cell product can vary with the donor, the tissue source and manufacturing. Researchers may still be developing tests that measure a product’s potency and consistency, which affects how results from one study apply to the next.
- Donor and recipient questions. Whether cells come from the patient or a donor changes the risks being studied, a distinction explained in autologous vs. allogeneic stem cells.
- Long follow-up. Because cells may persist or have delayed effects, safety follow-up can need to continue long after the treatment.
Other labels you may see on ClinicalTrials.gov:
| Label | Meaning |
|---|---|
| Early Phase 1 | Exploratory studies before traditional Phase 1, using very limited human exposure |
| Phase 1/2 or Phase 2/3 | A single study combining the goals of two phases |
| Phase 4 | Studies after a product is approved, to learn more about its use and safety |
| Not Applicable | Studies without an FDA-defined phase, such as many device, behavioral or procedure studies |
How to interpret a trial headline responsibly
| Phase | Main question | What it cannot prove |
|---|---|---|
| Phase 1 | Is it tolerable, and at what dose? | That it works |
| Phase 2 | Is there an early signal of benefit, and what dose should go forward? | That the benefit is real, large or lasting |
| Phase 3 | Does it work and is it safe enough in a larger, often controlled population? | Approval, which is a separate FDA decision |
A hypothetical press release, for practice. Suppose a release says: “Phase 2 trial shows stem cell therapy reduces knee pain by 40%.” This example is invented to show what to check.
- Results or registry status? Has a full paper or posted result been published, or is this a company announcement?
- How many people? Twenty participants and two hundred give very different confidence.
- Compared with what? If there was no placebo or comparison group, a 40% improvement cannot be attributed to the product.
- What was “40%”? A 40% change in average pain score, or 40% of participants improving by some amount?
- What about harms? Did the release report adverse events?
- What happens next? A Phase 2 result usually needs a larger trial before any conclusion about benefit.
Locating and reading the actual study record is covered in how to find stem cell clinical trials on ClinicalTrials.gov.
Phase 3 does not mean FDA-approved. It describes the study’s design stage, and a study labeled Phase 3 may not have started, may still be recruiting or may be ongoing; check its recruitment status and any posted results separately. Approval is a separate decision that comes after FDA reviews the evidence. A trial can be Phase 1/2; the label means one study is pursuing the goals of both phases.
Every stop on the Trials, cost and insurance line
- What Do Phase 1, 2, and 3 Mean in Stem Cell Clinical Trials?
- How to Find Stem Cell Clinical Trials on ClinicalTrials.gov
- How Much Does Stem Cell Therapy Cost in the United States?
- Does Health Insurance Cover Stem Cell Therapy in the United States?
Leave a note on this stop